Our results suggested that the serum levels of FGF21 may be related to obesity or hyperglycemia in patients with PTC, and that FGF21 promotes tumor progression via upregulation of the FGFR signaling axis, including phosphorylation of AKT and ERK. The gene discussed is AKT1; the disease is obesity due to melanocortin 4 receptor deficiency.